Tagged with Artificial Intelligence,

Opinion Drs David Higgins and Marco F Schmidt highlight the gap that exists between the abundant discussions around technological innovation in healthcare and implementation and why pharma needs to develop its own proprietary approaches to crunching ‘wide data’.   Data is the new oil, but biomedical data – despite its abundance…

Japan Ryu Ogawa and Satoshi Tamaki of Japanese AI-powered drug discovery firm Molcure outline how their technology can supercharge the speed and efficiency of the drug discovery process as well as the wider implications for greater use of artificial intelligence in the biotechnology field.   The greatest strength of Molcure’s system…

Opinion Dr Sophia Ononye-Onyia explains why a combination of both repurposed drugs and emerging technologies like 3D bioprinting and artificial intelligence will be crucial in beating COVID-19.   Much has already been said about the hundreds of vaccines that are currently in development for providing global protection against COVID-19 by leading…

Opinion DataArt’s Daniel Piekarz looks at how machine learning and artificial intelligence can play into the important task of drug repurposing, potentially providing solutions to the most pressing healthcare concerns of today, including the COVID-19 pandemic.   “Standing on the shoulders of giants” is a metaphor, made famous by Isaac Newton,…

Artificial Intelligence Artificial intelligence (AI) is increasingly being utilised in the drug discovery process, with the latest breakthrough being the development of an antibiotic that is powerful enough to combat resistant bacteria strains via a deep learning algorithm.   AI has the power to enable biopharmaceutical companies to reduce costs and improve…

Global Greg Reh leads Deloitte’s global life sciences sector which includes clients in biopharma, medtech, generics and distribution businesses, as well as non-profit patient advocacy organizations and regulatory agencies. He discusses talent acquisition and retention in global life sciences today, the challenges around data and AI uptake, and the future of…

Global With clinical trials having become extremely expensive to conduct, industry buzz around the potential of data and artificial intelligence (AI) to allay these costs has grown. However, experts are split as to the true potential of digital tools to reduce clinical development outlay and provide better patient outcomes in the…

UAE The Dubai Health Authority, the government body responsible for overseeing Dubai’s health system, is working full speed as the 2021 mark laid by the Dubai Health Strategy 2021 approaches. Director General HE Humaid Al Qutami, explains how the organization is working to provide the highest quality of medical care to…

Artificial Intelligence Digital health deal values in biopharma jumped to USD 6.4 billion in 2019, largely thanks to software company Dassault Systemes Americas Corp.’s USD 5.9 billion acquisition of health tech company Medidata Solutions, according to analysis by S&P Global Market Intelligence. “Traditional investors in the digital health startup space have generally…

Artificial Intelligence With so many wild predictions being bandied around about AI’s potential to radically transform healthcare for the better, it is easy to lose sight of the fact that materialization of that dream will be far from easy. Indeed, the task a hand can seem quite formidable. Most pharma companies’ existing…

Artificial Intelligence As data and information proliferate at an exponential pace, many industries have turned to artificial intelligence to make sense of this information and deliver meaningful insights that can enhance performance. This is certainly the case for the healthcare sector, where the technology augurs nothing less than a paradigm shift towards…

Artificial Intelligence On the supply side, AI appears to herald the prospect of de-risking the drug discovery process and doing away with many of the traditional time-consuming approaches at a juncture when drug development had been becoming financially unsustainable and clinical research organisations (CROs) had been systematically failing to improve operational efficiency.…